1. Home
  2. XGN vs DXR Comparison

XGN vs DXR Comparison

Compare XGN & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$4.26

Market Cap

71.2M

Sector

Health Care

ML Signal

HOLD

Logo Daxor Corporation

DXR

Daxor Corporation

HOLD

Current Price

$9.93

Market Cap

59.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XGN
DXR
Founded
2002
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.2M
59.0M
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
XGN
DXR
Price
$4.26
$9.93
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$8.86
N/A
AVG Volume (30 Days)
409.1K
2.2K
Earning Date
05-11-2026
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,446,345.00
Revenue This Year
$8.12
$44,935.22
Revenue Next Year
$13.00
$74.79
P/E Ratio
N/A
$33.83
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$8.45
52 Week High
$12.23
$14.76

Technical Indicators

Market Signals
Indicator
XGN
DXR
Relative Strength Index (RSI) 52.21 42.86
Support Level $3.23 $9.21
Resistance Level $5.55 $11.40
Average True Range (ATR) 0.41 0.65
MACD -0.10 -0.08
Stochastic Oscillator 10.42 7.03

Price Performance

Historical Comparison
XGN
DXR

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

About DXR Daxor Corporation

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.

Share on Social Networks: